Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Dec
15
Today In Oncology
Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer
Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo